If so, determining neonatal adiponectin levels could serve as a risk predictor for metabolic disease in later life and could eventually legitimate early dietary or even pharmacologic treatment with either adiponectin inducing agents or substances that mimic adiponectin effects. The gene discussed is ADIPOQ; the disease is metabolic disease.